NKGen Biotech Secures $25.8 Million Loan from AlpineBrook Capital

Reuters01-10

NKGen Biotech Secures $25.8 Million Loan from AlpineBrook Capital

NKGen Biotech, Inc. and its subsidiary, NKGen Operating Biotech, Inc., have entered into a secured promissory note with AlpineBrook Capital GP I Limited for a principal amount of $25.84 million. The note, which carries an interest rate of 12% per annum, matures two months after issuance, with the potential for extension at the lender’s discretion. The agreement documents previous cash advances primarily related to NKGen Biotech’s acquisition of a majority stake in NKGen Biotech Korea Co., Ltd. through the Korean bankruptcy process, as well as an incremental $300,000 advanced at the time of execution. The note includes a "most favored nation" provision, ensuring the lender receives terms at least as favorable as any future debt or equity financings, and grants the lender a right of first refusal on any proposed transfer of NKGen Korea shares by the company. Prepayment before maturity is prohibited without lender consent.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nkgen Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-003030), on January 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602304762?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-10 06:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602304762","market":"us","top_or_hot":-1,"title":"NKGen Biotech Secures $25.8 Million Loan from AlpineBrook Capital","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NKGen Biotech Secures $25.8 Million Loan from AlpineBrook Capital\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NKGen Biotech, Inc. and its subsidiary, NKGen Operating Biotech, Inc., have entered into a secured promissory note with AlpineBrook Capital GP I Limited for a principal amount of $25.84 million. The note, which carries an interest rate of 12% per annum, matures two months after issuance, with the potential for extension at the lender’s discretion. The agreement documents previous cash advances primarily related to NKGen Biotech’s acquisition of a majority stake in NKGen Biotech Korea Co., Ltd. through the Korean bankruptcy process, as well as an incremental $300,000 advanced at the time of execution. The note includes a \"most favored nation\" provision, ensuring the lender receives terms at least as favorable as any future debt or equity financings, and grants the lender a right of first refusal on any proposed transfer of NKGen Korea shares by the company. Prepayment before maturity is prohibited without lender consent.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NKGN\">Nkgen Biotech</a> Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-003030), on January 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NKGen Biotech Secures $25.8 Million Loan from AlpineBrook Capital</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNKGen Biotech Secures $25.8 Million Loan from AlpineBrook Capital\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-10 06:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NKGen Biotech Secures $25.8 Million Loan from AlpineBrook Capital\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NKGen Biotech, Inc. and its subsidiary, NKGen Operating Biotech, Inc., have entered into a secured promissory note with AlpineBrook Capital GP I Limited for a principal amount of $25.84 million. The note, which carries an interest rate of 12% per annum, matures two months after issuance, with the potential for extension at the lender’s discretion. The agreement documents previous cash advances primarily related to NKGen Biotech’s acquisition of a majority stake in NKGen Biotech Korea Co., Ltd. through the Korean bankruptcy process, as well as an incremental $300,000 advanced at the time of execution. The note includes a \"most favored nation\" provision, ensuring the lender receives terms at least as favorable as any future debt or equity financings, and grants the lender a right of first refusal on any proposed transfer of NKGen Korea shares by the company. Prepayment before maturity is prohibited without lender consent.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NKGN\">Nkgen Biotech</a> Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-003030), on January 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NKGN","symbol_name":"NKGen Biotech Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL7s6tLh:1","article_id":"2602304762","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602304762","pubTimestamp":1767997558,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NKGen Biotech, Inc. and its subsidiary, NKGen Operating Biotech, Inc., have entered into a secured promissory note with AlpineBrook Capital GP I Limited for a principal amount of $25.84 million. The note, which carries an interest rate of 12% per annum, matures two months after issuance, with the potential for extension at the lender’s discretion. The agreement documents previous cash advances primarily related to NKGen Biotech’s acquisition of a majority stake in NKGen Biotech Korea Co., Ltd. through the Korean bankruptcy process, as well as an incremental $300,000 advanced at the time of execution. The note includes a \"most favored nation\" provision, ensuring the lender receives terms at least as favorable as any future debt or equity financings, and grants the lender a right of first refusal on any proposed transfer of NKGen Korea shares by the company. Prepayment before maturity is prohibited without lender consent.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NKGN":"NKGen Biotech Inc.","BK4139":"生物科技"},"translate_title":"NKGen Biotech从AlpineBrook Capital获得2580万美元贷款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKGN":0.9},"content_text":"NKGen Biotech Secures $25.8 Million Loan from AlpineBrook Capital\n    \n\n        NKGen Biotech, Inc. and its subsidiary, NKGen Operating Biotech, Inc., have entered into a secured promissory note with AlpineBrook Capital GP I Limited for a principal amount of $25.84 million. The note, which carries an interest rate of 12% per annum, matures two months after issuance, with the potential for extension at the lender’s discretion. The agreement documents previous cash advances primarily related to NKGen Biotech’s acquisition of a majority stake in NKGen Biotech Korea Co., Ltd. through the Korean bankruptcy process, as well as an incremental $300,000 advanced at the time of execution. The note includes a \"most favored nation\" provision, ensuring the lender receives terms at least as favorable as any future debt or equity financings, and grants the lender a right of first refusal on any proposed transfer of NKGen Korea shares by the company. Prepayment before maturity is prohibited without lender consent.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nkgen Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-003030), on January 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602304762","isCrawlerRequest":true}